- Ipsen’s oncology revenue for the third quarter was €604.0 million, exceeding estimates of €591.9 million.
- The neuroscience division recorded revenues of €181.9 million, surpassing projected figures of €177.7 million.
- Revenue from rare diseases reached €50.8 million, slightly below the estimated €53.8 million.
- Financial guidance for 2024 has been revised upward, with expected total sales growth of over 8.0% at constant exchange rates, compared to the previous guidance of over 7.0%.
- The core operating margin is expected to exceed 31.0% of total sales, an increase from the prior guidance of over 30.0%.
- Analyst recommendations include 7 buy ratings, 12 hold ratings, and no sell ratings.
A look at Ipsen SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using the Smartkarma Smart Scores have indicated a positive long-term outlook for Ipsen SA, a company that manufactures and markets medical drugs for various disease areas. With a strong score in resilience and momentum, Ipsen SA is positioned well to weather market fluctuations and capitalize on growth opportunities in the future. While the value and dividend scores are moderate, the company’s emphasis on growth and ability to adapt to changing market conditions are key strengths that analysts have highlighted.
In summary, Ipsen SA, known for its broad range of medical drugs targeting oncology, endocrinology, and neuromuscular disorders, is showing resilience and momentum in its overall outlook. Analysts are optimistic about the company’s future prospects based on its ability to navigate challenges and maintain growth momentum in the competitive pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
